A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin ... have sent a letter (PDF) to Novo Nordisk to request more ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations.

Novo Nordisk A/S’s Wegovy helped treat an obesity-associated liver disease in a late-stage trial, potentially adding to its status as a weight-loss medicine that can treat and prevent several ...

Novo Nordisk A/S has fallen behind Eli Lilly & Co. this year in the race to be the big stock market winner from obesity drugs. Analysts expect the Danish company to start catching up. Less than a ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. The regulatory reprimand ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.

This marks Novo Nordisk's second win this year in treating ... In March, Wegovy was granted an expanded indication from the Food and Drug Administration (FDA) to help treat patients with obesity ...

All doses of Novo Nordisk’s blockbuster diabetes and obesity treatments are listed as available on the Food and Drug Administration’s drug shortage list as of Wednesday, raising the ...

Danish pharmaceutical company Novo Nordisk (NYSE: NVO ... In March, Wegovy was granted an expanded indication from the Food and Drug Administration (FDA) to help treat patients with obesity ...

In the latest trading session, Novo Nordisk (NVO) closed at $112.46, marking a -0.82% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile ...